Intelligent Manufacturing Platform for Advanced CAR Therapies
| Title | Intelligent Manufacturing Platform for Advanced CAR Therapies |
|---|---|
| Acronym | IMPACT - EC |
| Start date | 2026-09-01 |
| End date | 2031-08-31 |
| Sponsor | European Commission |
| Institution | University of Barcelona |
| Principal investigator | Josep M Canals
E-Mail: jmcanals@ub.edu |
Associated cell lines
- GENEAe020-A (GENEA019)
- RCe013-A (RC-9, RC9)
- WAe009-A (H9, WA09)
- WTSIi018-B-18 (Kolf 2.1 J (TARDBP M337V WT/SNV))
Project Description
IMPACT is a European project aimed at improving the manufacturing of advanced cell therapies for the treatment of blood cancers. Although these therapies have demonstrated high effectiveness, their wider adoption remains limited due to complex production processes, high costs, and scalability challenges. The project brings together an international consortium to develop solutions that optimize different stages of production, enhancing quality, efficiency, and patient adaptability. It also promotes the use of innovative technologies to assess treatment safety and efficacy in a more predictive manner, while reducing reliance on animal testing. IMPACT incorporates advanced digital tools to improve process control and ensure traceability, in line with stringent quality standards. In addition, it integrates environmental sustainability principles and supports workforce training to facilitate the uptake of these technologies. Overall, the project aims to make these therapies more accessible by reducing costs and production times, while establishing a foundation for future manufacturing approaches in the field of advanced therapies.